Rajkumar S, Mateos M, Schaeffer M, Lin X, Bathija S, Gupta-Werner N
Blood Cancer J. 2024; 14(1):215.
PMID: 39638995
PMC: 11621302.
DOI: 10.1038/s41408-024-01170-z.
Faupel-Badger J, Kohaar I, Bahl M, Chan A, Campbell J, Ding L
Nat Rev Cancer. 2024; 24(11):792-809.
PMID: 39354069
DOI: 10.1038/s41568-024-00744-0.
Abdallah N, Witzig T, Kumar S, Lacy M, Hayman S, Dispenzieri A
Leukemia. 2024; 38(5):1169-1171.
PMID: 38418610
DOI: 10.1038/s41375-024-02192-z.
Abdallah N, Lakshman A, Kumar S, Cook J, Binder M, Kapoor P
Blood Cancer J. 2024; 14(1):9.
PMID: 38228628
PMC: 10791688.
DOI: 10.1038/s41408-024-00980-5.
Wang M, Yu Y, Liu L, Schoen M, Kumar A, Vargo K
JCO Clin Cancer Inform. 2023; 7:e2300081.
PMID: 38048516
PMC: 10703129.
DOI: 10.1200/CCI.23.00081.
Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients.
Rajkumar S, Abdallah N, Lakshman A, Kumar S, Cook J, Binder M
Res Sq. 2023; .
PMID: 37961238
PMC: 10635305.
DOI: 10.21203/rs.3.rs-3378634/v1.
SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.
Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A
EClinicalMedicine. 2023; 58:101910.
PMID: 36969337
PMC: 10033724.
DOI: 10.1016/j.eclinm.2023.101910.
Prevalence of smoldering multiple myeloma based on nationwide screening.
Thorsteinsdottir S, Gislason G, Aspelund T, Rognvaldsson S, Oskarsson J, Sigurdardottir G
Nat Med. 2023; 29(2):467-472.
PMID: 36747117
PMC: 11099842.
DOI: 10.1038/s41591-022-02183-6.
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.
Saldarriaga M, Darwiche W, Jayabalan D, Monge J, Rosenbaum C, Pearse R
Front Oncol. 2022; 12:1020011.
PMID: 36387095
PMC: 9646612.
DOI: 10.3389/fonc.2022.1020011.
How I approach smoldering multiple myeloma.
Vaxman I, Gertz M
Blood. 2022; 140(8):828-838.
PMID: 35576526
PMC: 9412010.
DOI: 10.1182/blood.2021011670.
Smoldering multiple myeloma: Reviewing the rationale for intervention.
Gertz M
Leuk Lymphoma. 2022; 63(9):2033-2040.
PMID: 35532298
PMC: 9719610.
DOI: 10.1080/10428194.2022.2068008.
Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
Chojnacka M, Diamond B, Landgren O, Maura F
Semin Oncol. 2022; 49(1):11-18.
PMID: 35168813
PMC: 9149131.
DOI: 10.1053/j.seminoncol.2022.01.006.
The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.
Ojo A, Ojukwu S, Asemota J, Akinyemi O, Araoye M, Saleh M
J Cancer Res Clin Oncol. 2022; 148(4):897-911.
PMID: 35059867
DOI: 10.1007/s00432-022-03920-7.
Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Lussier T, Schoebe N, Mai S
Cells. 2022; 11(1).
PMID: 35011692
PMC: 8750018.
DOI: 10.3390/cells11010130.
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
Landgren O
Hematology Am Soc Hematol Educ Program. 2021; 2021(1):662-672.
PMID: 34889381
PMC: 8791104.
DOI: 10.1182/hematology.2021000303.
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
Visram A, Cook J, Warsame R
Hematology Am Soc Hematol Educ Program. 2021; 2021(1):673-681.
PMID: 34889380
PMC: 8791169.
DOI: 10.1182/hematology.2021000304.
Genome Instability in Multiple Myeloma: Facts and Factors.
Aksenova A, Zhuk A, Lada A, Zotova I, Stepchenkova E, Kostroma I
Cancers (Basel). 2021; 13(23).
PMID: 34885058
PMC: 8656811.
DOI: 10.3390/cancers13235949.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, van de Donk N
Haematologica. 2021; 106(11):2799-2812.
PMID: 34261295
PMC: 8561280.
DOI: 10.3324/haematol.2021.278519.
Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
Tessier C, Allard T, Boudreault J, Kaedbey R, Ethier V, Fortin F
Curr Oncol. 2021; 28(3):2029-2039.
PMID: 34073289
PMC: 8161809.
DOI: 10.3390/curroncol28030188.
Quantitative, Dynamic F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report.
Sachpekidis C, Turk M, Dimitrakopoulou-Strauss A
Diagnostics (Basel). 2021; 11(4).
PMID: 33916783
PMC: 8066752.
DOI: 10.3390/diagnostics11040649.
